Dr Athanasios Papadopoulos joined Emergex as Chief Medical Officer and Vice President of Global Clinical Development in February 2019. He is responsible for providing leadership and direction on the development of Emergex’s growing pipeline of vaccines.
Dr Athan has extensive pharmaceutical and vaccine clinical development expertise gained through more than 20 years of experience in industry.
He previously held senior leadership roles at multinational pharma companies Sanofi and Novartis, where he led scientific strategy and full integration of clinical development programs, like the ones for vaccines Dengvaxia® (against Dengue fever) and Bexsero® (against Meningitis B), respectively.
He has also made significant contributions to product development in therapeutic areas such as autoimmune diseases, oncology and cardiovascular conditions, including filing several submissions to regulatory authorities worldwide e.g. FDA, EMA, ANVISA, KFDA, etc.
Dr Athan is a GMC-registered medical doctor trained as a clinical bio-pathology specialist.